InMed Pharmaceuticals Inc. (INM)

Market Cap	3.86M
Revenue (ttm)	1.61M
Net Income (ttm)	-16.96M
Shares Out	3.33M
EPS (ttm)	-24.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	70,680
Open	1.18
Previous Close	1.21
Day's Range	1.12 - 1.21
52-Week Range	0.92 - 35.50
Beta	0.95
Analysts	Sell
Price Target	20.40 (+1,689.47%)
Earnings Date	May 12, 2023

About INM

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Eric Adams
• Employees: 13
• Stock Exchange: NASDAQ
• Ticker Symbol: INM

Analyst Forecast

According to 8 analysts, the average rating for INM stock is "Sell." The 12-month stock price forecast is $20.4, which is an increase of 1,689.47% from the latest price.

Price Target

$20.4

(1,689.47% upside)

Analyst Consensus: Sell